Apr 18 |
DiaMedica (DMAC) Up as Stroke Study Dosing Begins Post Relaunch
|
Apr 17 |
DiaMedica Therapeutics Announces First Patient Dosed in Relaunch of its Pivotal Phase 2/3 ReMEDy2 Trial of DM199 for the Treatment of Acute Ischemic Stroke
|
Mar 21 |
DiaMedica Therapeutics files for $100M mixed securities shelf
|
Mar 21 |
DiaMedica Therapeutics Inc.'s (NASDAQ:DMAC) Path To Profitability
|
Mar 20 |
DiaMedica Therapeutics Inc. (DMAC) Q4 2023 Earnings Call Transcript
|
Mar 19 |
DiaMedica Therapeutics GAAP EPS of -$0.60 in-line
|
Mar 19 |
DiaMedica Therapeutics Provides a Business Update and Announces Full Year 2023 Financial Results
|
Jan 29 |
DiaMedica Therapeutics Announces Poster Presentation at International Stroke Conference
|
Jan 7 |
DiaMedica Therapeutics Inc.'s (NASDAQ:DMAC) largest shareholders are individual investors with 52% ownership, insiders own 37%
|
Dec 11 |
Here's Why We're Not Too Worried About DiaMedica Therapeutics' (NASDAQ:DMAC) Cash Burn Situation
|